1. The Board approved grant of authority Mr. Narayan Kutty Menon (DIN 01111297), Whole-time Director & CEO to Identify Buyers and Negotiate Terms w.r.t proposed sale of the Company's factory ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories' board, meeting on 27th November 2025, authorized its Whole-time Director & CEO Mr. Narayan Kutty Menon to identify buyers and negotiate terms for the proposed sale of the company's factory premises. Shareholders had already cleared this sale via a special resolution passed through postal ballot on 1st November 2025 under Section 180(1)(a) of the Companies Act, 2013. Separately, the board appointed Ms. Falguni Kumawat, a qualified Company Secretary with ICSI Membership No. A37989 and 10 years of experience in secretarial, legal and finance functions, as the new Company Secretary and Compliance Officer effective 1st December 2025. The filing (BSE code 31210) was signed by Additional Director Vijaya Mani, who holds DIN 11353910.
The factory sale is now in active execution phase, which could unlock cash or signal a restructuring of operations — shareholders should watch for the final sale price and use of proceeds. The Company Secretary appointment is a routine compliance transition and not material to stock price.